| these results reveal an unrecognized role for CD44 in oncogenic Kras-induced lung adenocarcinoma and suggest that targeting CD44 could be an effective strategy for halting Kras-dependent carcinomas. | lung, |
| data identifies Kras* as a key oncogene in pancreatic cancer maintenance, but raises the possibility of acquired resistance should Kras inhibitors become available for use in pancreatic cancer | pancreatic, |
| A rare point mutation in the Ras oncogene in hepatocellular carcinoma. | liver, |
| The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. | colorectal, |
| Findings support the development of ISG15 conjugation inhibitors for treating breast and also other cancers expressing oncogenic Ki-Ras. | breast, |
| MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). | colorectal, |
| Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy. | leukemia, |
| cell-autonomous phosphoinositide 3-kinase and 3-phosphoinositide-dependent protein kinase 1 are key effectors of oncogenic Kras in the pancreas, mediating cell plasticity, acinar-to-ductal metaplasia, and pancreatic ductal adenocarcinoma formation | pancreatic, |
| Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. | colorectal, |
| The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. | lung, |
| Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. | colorectal, |
| the reprogramming of glutamine metabolism is mediated by oncogenic KRAS, the signature genetic alteration in pancreatic ductal adenocarcinoma, through the transcriptional upregulation and repression of key metabolic enzymes in this pathway | pancreatic, |
| Involvement of Gpr125 in the myeloid sarcoma formation induced by cooperating MLL/AF10(OM-LZ) and oncogenic KRAS in a mouse bone marrow transplantation model. | sarcoma, |
| regulates pancreatic acinar plasticity and constrains pancreatic neoplasia driven by oncogenic Kras | pancreatic, |
| The ectopic expression of miR-433 and mir-127 in gastric cancer cell lines inhibits cell proliferation, cell migration and invasion by interacting with the mRNA encoding oncogenic factors KRAS and MAPK4 respectively. | gastric, |
| Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. | lung, |
| Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells. | leukemia, |
| Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer. | pancreatic, |
| Trisomy of Dscr1 suppresses the progression of pancreatic intraepithelial neoplasia-1A (PanIN-1A) to PanIN-1B lesions without affecting the initiation of PanIN lesions mediated by oncogenic Kras(G12D). | pancreatic, |
| Expression of ras oncogene p21 in prostate cancer. | prostate, |